Omniferon

Omniferon

Immunology A purified IFN derived from human WBCs for treating viral and other immune disorders–eg, HBV, HCV, HIV/AIDS, herpes, CML, multiple sclerosis. See Interferon.
References in periodicals archive ?
Omniferon is currently in Phase II clinical studies in Europe for hepatitis C.
stated, "In combining Viragen's proprietary natural alpha-interferon, Omniferon, with Zonagen's formulation, we anticipate that the delivery of the drug across the skin layers will be enhanced, potentially giving a more effective treatment for this debilitating disease.
The collaborators will utilize PolyMASC's novel protoMASC PEGylation process to deliver Viragen's lead drug, Omniferon, a natural alpha interferon currently in Phase II clinical trials in Europe for hepatitis C.
Since Omniferon is a naturally occurring alpha-interferon, it is expected to have an improved side-effect profile over recombinant products.
The development of a PEGylated Omniferon using PolyMASC's novel technology keeps Viragen at the forefront of immunotherapy and fits perfectly into our clinical development plan for hepatitis C.
Viargen uses white blood cells as the source material for the manufacture of Omniferon, its proprietary, multi-subtype, highly purified natural alpha interferon drug currently in preclinical studies.
The potential access to all filtered white blood cells increases Viragen's capability to maximize production of Omniferon," said Gerald Smith, Chairman & CEO of Viragen.
Produced in its Scottish facility, Viragen's lead product, Omniferon, is currently in Phase II clinical trials in Europe for hepatitis C, a disease estimated to afflict tens of millions worldwide.
Viragen plans to initially develop Omniferon for hepatitis C, a viral infection of the liver that afflicts approximately 4 million Americans and more than 170 million people worldwide.
is currently constructing a manufacturing facility in Edinburgh, Scotland for the production of Omniferon, the Company's second generation natural human alpha interferon product.
The company plans to undertake clinical studies in Europe for testing Omniferon in the treatment of such diseases as multiple sclerosis, HIV/AIDS, hepatitis B & C and certain cancers.
Viragen has exclusively licensed its subsidiary to produce Omniferon for production and testing within the European Union.